SCHEMBL10107355

SCHEMBL10107355

C=C(C)OC(=O)N1CCC(CNCc2nc(-c3ccncc3)no2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.52
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
LMNA P02545 5/20 0.43
TSHR P16473 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
RECQL P46063 2/20 0.42
CHRNA7 P36544 1/20 0.41
NAMPT P43490 1/20 0.41
KMT2A Q03164 2/20 0.40
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 1/20 0.40
HDAC4 P56524 1/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39
GRIN2B Q13224 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4523547 0.86 GPR119 (0.70) GPR119HDAC8HDAC6LMNATSHR
SCHEMBL10107598 0.85 GPR119 (0.57) GPR119LMNATSHRSMN1; SMN2RECQL
SCHEMBL4520300 0.83 TSHR (0.51) GPR119LMNATSHRSMN1; SMN2RECQL
SCHEMBL10107592 0.82 GPR119 (0.49) GPR119LMNATSHRSMN1; SMN2RECQL
SCHEMBL10107534 0.81 KMT2A (0.61) GPR119LMNATSHRSMN1; SMN2NAMPT
SCHEMBL10107332 0.76 GPR119 (0.60) GPR119LMNATSHRSMN1; SMN2RECQL
SCHEMBL4421911 0.74 GPR119 (0.54) GPR119HDAC4
SCHEMBL390268 0.74 GPR119 (0.75) GPR119HDAC6LMNATSHRSMN1; SMN2
SCHEMBL386914 0.74 GPR119 (0.72) GPR119HDAC6LMNATSHRSMN1; SMN2
SCHEMBL390317 0.73 GPR119 (0.74) GPR119HDAC6LMNATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207147-B2 Heterocyclic derivatives as GPCR receptor agonists PROSIDION LIMITED (GB) 2012-06-26 US disclosed
US-20090281060-A1 HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281060-A1 HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS GPR119, GCGR, GLP1R GPR119 1/4885HDAC8 1933/4885HDAC6 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.